Multiple Sclerosis (MS)
Conditions
Brief summary
In collaboration with the Mercy MS Achievement Center, Lumos Labs is proposing an open-label, 12-month pilot study of computerized cognitive training as part of the cognitive wellness program in order to evaluate (1) the user experience of Lumosity in individuals with MS, and (2) the efficacy of Lumosity for improving cognitive outcomes in individuals with MS.
Detailed description
Approximately 50 current members of the Mercy MS Achievement Center will be provided with 12-month premium access Lumosity accounts. Study participants must be ≥18 years of age, and currently members of the Achievement Center participating in the cognitive wellness program. Those who consent will be provided with an account activation code and instructed on how to sign up for Lumosity. Upon creating an account, users would be asked to complete a short demographic survey (Information About You, which includes age, sex, race/ethnicity, education, occupation) and two additional short surveys: a Computer Experience Questionnaire and a Perceptions of Brain Training questionnaire. In addition, participants will be assessed with the Montreal Cognitive Assessment (MOCA), and be directed to take the Brain Performance Test (on a laptop or desktop computer) within the first 7 days of creating their account. If not conducted within the previous 3 months, participants would also be required to have the following assessments at baseline (i.e., within the first 7 days): Multiple Sclerosis Neuropsychological Questionnaire (MSNQ), Multiple Sclerosis Impact Scale-29 (MSIS-29), and Beck Depression Inventory (BDI). After one week of using Lumosity, and then every other month for 12 months, participants would be asked to complete a short questionnaire about their experience with Lumosity. Every 3 months, participants would repeat the BPT, MSNQ, and BDI; and every 6 months, they would repeat the MSIS. Finally, at the end of the study, the end of the study they would also repeat the MOCA.
Interventions
DEVICELumosity
Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
Sponsors
Dignity Health
Lumos Labs, Inc.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Participants must meet the following criteria: 1. Signed informed consent 2. 18 years of age or older, 3. English-speaking, 4. Current participants in the MS Achievement Center Cognitive Wellness Program 5. Sufficient physical capacity to use a computer keyboard and mouse 6. Willing and able to use Lumosity at least 3 times per week
Exclusion criteria
Participants who meet any of the following criteria will be excluded from participation: 1. Under 18 years of age 2. Are taking medication that may impede cognitive functioning 3. Have other conditions or problems that may preclude regular computer usage
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Performance Characteristics and Usability measures of Lumosity, as measured by Self-Report Descriptive Questionnaires | 1 year | The primary objective is to determine performance characteristics and usability of Lumosity in individuals with MS as measured through qualitative questionnaires. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of Lumosity in individuals with MS, as measured with the MSNQ | 1 Year | To determine the efficacy of Lumosity in this study population as measured by • Change from baseline on the MSNQ at 12 months |
| Efficacy of Lumosity in individuals with MS, as measured with the MOCA | 1 Year | To determine the efficacy of Lumosity in this study population as measured by • Change from baseline on the MOCA at 12 months |
| Efficacy of Lumosity in individuals with MS, as measured with the BPT | Change from baseline as measured at 3, 6, 9 and 12 months | To determine the efficacy of Lumosity in this study population as measured by change from baseline on the BPT Grand Index score and scaled subtest scores at 3, 6, 9, and 12 months |
| Efficacy of Lumosity in individuals with MS, as measured with the BDI. | 1 Year | To determine the efficacy of Lumosity in this study population as measured by • Change from baseline on the BDI at 12 months |
| Engagement - as measured by number of unique days played and number of games played | 1 year | To determine the level of engagement with Lumosity in individuals with MS as measured by number of unique days and number of games played |
| Efficacy of Lumosity in individuals with MS, as measured with the MSIS-29. | 1 Year | To determine the efficacy of Lumosity in this study population as measured by • Change from baseline on the MSIS-29 at 12 months |
Outcome results
None listed